Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).
One month after publishing data that showed the multiple sclerosis drug siponimod generated significant improvements in patients, including a 21 percent decrease in the risk of disease progression, Novartis released new information demonstrating the drug consistently reduced the risk of confirmed disability progression in secondary progressive multiple sclerosis (SPMS) patients.
With growing concerns about the rise of drug resistant bacteria, multiple companies are developing new forms of antimicrobials to take on serious health concerns, such as carbapenem-resistant enterobacteriaceae (CRE), Clostridium difficile (C. diff) or Staphylococcus infections.
Biogen handed more than $1 billion to Ionis Pharmaceuticals to support a new 10-year collaboration to develop novel antisense drug candidates for a broad range of neurological diseases.
Med Ad News – the leading pharmaceutical business and marketing publication – reveals the winners for the 2018 Manny Awards, celebrating the healthcare communications industry.
Merck KGaA will seek development partners for experimental treatments including tepotinib as the German company looks to licensing deals to help fund clinical trials, according to its head of drug R&D.
The use of artificial intelligence and machine learning in drug development has been ramping up and investors are taking keen notice of the growing trend. London-based BenevolentAI snagged $115 million to give the company a total of about $200 million in its coffers.
An advisory panel to the U.S. Food and Drug Administration unanimously voted in favor of approving the first cannabis-derived medicine in the country, a childhood epilepsy treatment developed by GW Pharma.
According to Reuters UK, Japan’s Takeda Pharmaceutical made an official bid to acquire London’s Shire for about $60 billion, which was rejected.
U.S. FDA staff flagged concerns about potentially fatal blood clots from higher doses of a rheumatoid arthritis drug developed by Eli Lilly and Co. and Incyte Corp.
Novartis’ first quarterly results under new CEO Vas Narasimhan were marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by the company’s U.S. generics unit.
CHICAGO, IL. (April 18, 2018) — Intouch Solutions proudly announces the promotion of four employees in its Chicago office. A leading marketing agency serving the pharmaceutical industry, Intouch Solutions has seen rapid expansion over the past five years and actively promotes within the 700-person firm. The four employees include: Ashley Muelhausen, account supervisor, joined the […]
U.S. regulators expanded use of AstraZeneca’s lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation.
APRIL 18th, 2018 – New York, NY – Precision for Value, the market leader in supporting global pharmaceutical and life sciences companies in demonstrating the value and outcomes of innovative medical products, today announced significant additions to its Payer Strategy Team with the hiring of former payer executives Marylou Buyse, Joe Honcz, and Elizabeth Oyekan. […]
LONDON AND NEW YORK (April 18, 2018) — McCann Health, one of the most creatively awarded healthcare communications networks in the world, and part of McCann Worldgroup, today announced the launch of the McCann Health Global Scientific Council, adding a third pillar of scientific prowess to its existing pillars of strategy and creativity. The Council, […]
Gene-editing technologies that alter mosquitoes’ DNA could prove critical in the fight against malaria, Bill Gates said, and ethical concerns should not block progress in such gene-modifying research.
Sangamo Therapeutics recently filed a notice with the U.S. SEC describing a data security breach.
Eli Lilly unveiled final data from the MONARCH 3 study that helped the drug garner FDA approval in February 2018 for the treatment of some breast cancer patients.
Janssen Pharmaceuticals has teamed up with Bristol-Myers Squibb to drive BMS-986177, a Factor XIa (FXIa) inhibitor, into Phase II development for the study of secondary stroke prevention and major thrombotic conditions.
A European decision to exclude Britain from the EU’s drug approval system from March 30, 2019 – the day after Brexit – has raised alarm among drugmakers, who fear the abrupt change could disrupt medicine supplies to patients.